Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant darovasertib before plaque brachytherapy or enucleation for early-stage uveal melanoma
NL-OMON59444Phase 3Not yet recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darovasertib in intraocular melanoma (4 cohorts), sponsored by IDEAYA Biosciences. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON59444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59444.